SGMO
SANGAMO THERAPEUTICS, INC
NASDAQ · Healthcare · Biotechnology · US
$0.07
+0.00%Latest reported
- Last report date
- May 14, 2026
- EPS actual
- -$0.08
- EPS estimate
- $0.01
- Revenue actual
- $1.4M
- Revenue estimate
- $33.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -500.8%
- Revenue beats (12Q)
- 4
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| May 14, 2026 | $0.01 | -$0.08 | Miss -1700.00% | $1.4M |
| Nov 6, 2025 | -$0.03 | -$0.11 | Miss -266.67% | — |
| Aug 7, 2025 | -$0.07 | -$0.08 | Miss -14.29% | $18.3M |
| Mar 17, 2025 | -$0.09 | -$0.11 | Miss -22.22% | $7.6M |
| May 9, 2024 | -$0.22 | -$0.27 | Miss -22.73% | $481.0K |
| Mar 13, 2024 | -$0.25 | -$0.34 | Miss -36.00% | $2.0M |
| Nov 1, 2023 | -$0.33 | -$0.34 | Miss -3.03% | $9.4M |
| Feb 22, 2023 | -$0.36 | -$0.32 | Beat 11.11% | $27.2M |
| Nov 3, 2022 | -$0.35 | -$0.34 | Beat 2.86% | $26.5M |
| Aug 4, 2022 | -$0.35 | -$0.29 | Beat 17.14% | $29.4M |
| May 5, 2022 | -$0.32 | -$0.30 | Beat 6.25% | $28.2M |
| Feb 24, 2022 | -$0.34 | -$0.26 | Beat 23.53% | $28.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 14, 2026